Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. This represents a 11.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN traded up $0.36 on Tuesday, reaching $53.10. The company’s stock had a trading volume of 287,241 shares, compared to its average volume of 1,273,068. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $55.79. The stock has a market capitalization of $3.23 billion, a P/E ratio of -31.87 and a beta of 0.24. The stock’s 50-day moving average is $45.75 and its two-hundred day moving average is $37.69.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. Equities analysts forecast that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ELVN. Stifel Nicolaus increased their price target on Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Mizuho lifted their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $70.50.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently added to or reduced their stakes in ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after purchasing an additional 1,693 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after purchasing an additional 80,506 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Enliven Therapeutics during the 1st quarter valued at about $578,000. Legal & General Group Plc raised its holdings in Enliven Therapeutics by 52.2% during the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock worth $646,000 after buying an additional 11,058 shares during the period. Finally, Quantbot Technologies LP raised its stake in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.